These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046 [TBL] [Abstract][Full Text] [Related]
6. Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians. al-Hadidi HF; Irshaid YM; Rawashdeh NM Eur J Clin Pharmacol; 1994; 47(4):311-4. PubMed ID: 7875180 [TBL] [Abstract][Full Text] [Related]
7. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa. Sommers DK; Moncrieff J; Avenant J Hum Toxicol; 1989 Jan; 8(1):39-43. PubMed ID: 2714809 [TBL] [Abstract][Full Text] [Related]
8. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Sommers DK; Moncrieff J; Avenant J Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305 [TBL] [Abstract][Full Text] [Related]
15. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Lennard MS; Tucker GT; Silas JH; Woods HF Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665 [TBL] [Abstract][Full Text] [Related]
16. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Horai Y; Taga J; Ishizaki T; Ishikawa K Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455 [TBL] [Abstract][Full Text] [Related]
18. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974 [TBL] [Abstract][Full Text] [Related]